[Skip to Navigation]
Comment & Response
June 29, 2022

Explanation for Error in Types of Medicare Patients Included in Aortic Valve Replacement Study

Author Affiliations
  • 1Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston
JAMA Cardiol. 2022;7(8):878. doi:10.1001/jamacardio.2022.1760

To the Editor On behalf of my coauthors, I write to report important errors in our Research Letter, “Days at Home after Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients”1 published Online First on October 20, 2021, and in the January 2022 issue of JAMA Cardiology. In this article, we reported the results of a post hoc analysis that was conducted between June 19, 2012, and June 30, 2018, of the Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients (SURTAVI) trial linked to Medicare claims. We compared the total number of days spent at home within the first year among intermediate-risk patients participating in this trial of transcatheter aortic valve replacement (TAVR) with a self-expanding bioprosthesis vs surgical aortic valve replacement (SAVR). We reported that “that intermediate-risk patients undergoing TAVR had approximately 9 more days at home 1 year after the procedure compared with those undergoing SAVR as a result of shorter index hospitalizations and fewer days in SNFs [skilled nursing facilities] and rehabilitation.”1

Add or change institution